JW Therapeutics Presents Latest Data of Carteyva® at 2022 ASCO Annual Meeting
- Sunday, June 5, 2022, 7:04
- Finance
- Add a comment
SHANGHAI, June 5, 2022 /PRNewswire/ — JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, presented the latest data of three clinical studies on Carteyva® (relmacabtagene…
About the Author
adminasapcorp has written 41558 stories on this site.